Who is it for?
According to the data from clinical trials, MitraClip and Pascal are promising for treating severe mitral valve regurgitation in patients with severe symptoms but are not good candidates for open-heart surgery to repair or replace their valve. Both can give these patients a shot at feeling better and living longer.
Data from a clinical research study called the Endovascular Valve Edge-to-Edge Repair Study II (EVEREST II) High Risk Registry (HRR), found that after one year, patients who underwent the experimental procedure had a survival rate of 75% versus a survival rate of 55% for patients who received medication only. Additionally, after a year, 74% of survivors had no or only slight limitations on physical activity.